Alterity Therapeutics Ltd. Sponsored ADR (ATHE)
译 Alterity Therapeutics up big on advancement of ATH434 for Parkinsonian disorder Alterity Therapeutics (NASDAQ:ATHE) is up 71% premarket after receiving FDA guidance in relation to the development pathway for ATH434 (previously PBT434), company's lead compound for the treatment of Multiple System Atrophy (MSA), a Parkinsonian disorder ... The company met with the FDA to obtain input on the developmental plan for ATH434, including feedback on the Phase 2 study design ... Alterity reached agreement with the FDA on the non-clinical investigations required to support the Phase 2 study, along with patient population, safety monitoring plan, and strategy for evaluating drug exposure during the study.
SeekingAlpha · 06-30 18:24